Searching the RRID Resource Information Network
Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.
SciCrunch Registry is a curated repository of scientific resources, with a focus on biomedical resources, including tools, databases, and core facilities - visit SciCrunch to register your resource.
| Resource Name | Proper Citation | Abbreviations | Resource Type |
Description |
Keywords | Resource Relationships | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Nuclear Receptor Cistrome Resource Report Resource Website 1+ mentions |
Nuclear Receptor Cistrome (RRID:SCR_014515) | data or information resource, database | A web-interface that enables users to access and download the processed ChIP chip/seq data of nuclear receptors, co-regulators and histone modifications. The web resources also includes processed differential expression data under ligand induction in conditions matched to ChIP_chip/seq data whenever possible. All the ChIP chip/seq peak regions are annotated with enriched HRE and co-regulator motifs. A list of predicted hormone response genes from integration of nuclear receptor ChIP chip/seq data and differential expression data is also readily available to the users. | database, nuclear receptor, web interface, chip, histone, peak |
is listed by: Nuclear Receptor Signaling Atlas is listed by: NIDDK Information Network (dkNET) |
Public, Available to the research community | SCR_014515 | SciCrunch Registry | NR Cistrome | 2026-09-26 02:18:53 | 1 | |||||||||
|
University of Michigan Center for Gastrointestinal Research In Vivo Animal and Human Studies Core Resource Report Resource Website 1+ mentions |
University of Michigan Center for Gastrointestinal Research In Vivo Animal and Human Studies Core (RRID:SCR_015608) | biomaterial supply resource, material resource, tissue bank | Core facility that consists of the following 4 distinct programs: In Vivo Small Animal Studies Program, Organoid/Enteroid Modeling Program, Biospecimens Banking Service, and Clinical Design and Statistics. | in vivo, animal and human studies, gastrointestinal research |
is listed by: NIDDK Information Network (dkNET) has parent organization: University of Michigan Center for Gastrointestinal Research is organization facet of: University of Michigan Center for Gastrointestinal Research |
digestive disease | NIDDK P30 DK034933 | Available to affiliated researchers | SCR_015608 | SciCrunch Registry | 2026-09-26 02:18:55 | 1 | ||||||||
|
GATACA GUDMAP Gene Explorer Resource Report Resource Website |
GATACA GUDMAP Gene Explorer (RRID:SCR_014518) | data or information resource, database | A database which can be used to search for genes critical for a variety of Genito-Urinary system functions and diseases. | genito-urinary system, genes, genetic diseases |
uses: GUDMAP Ontology is listed by: NIDDK Information Network (dkNET) has parent organization: GenitoUrinary Development Molecular Anatomy Project |
NIDDK | Freely available | SCR_014518 | SciCrunch Registry | 2026-09-26 02:18:53 | 0 | |||||||||
|
University of Chicago Digestive Diseases Research Core Center Tissue and Cell Imaging Core Resource Report Resource Website |
University of Chicago Digestive Diseases Research Core Center Tissue and Cell Imaging Core (RRID:SCR_015607) | biomaterial supply resource, material resource, tissue bank | Core whose services include anatomic pathology review of human and experimental animal tissues as well as consultation in the best approaches for such analyses, cost-effective and high quality processing and staining of formalin-fixed paraffin-embedded tissues, and making collections of human tissue and imaging technologies available to researchers. | tissue and cell imaging, gastrointestinal pathology, imaging technology, anatomic pathology |
is listed by: NIDDK Information Network (dkNET) has parent organization: University of Chicago Digestive Diseases Research Core Center is organization facet of: University of Chicago Digestive Diseases Research Core Center |
digestive disease | NIDDK P30 DK042086 | Available to the research community, Available to affiliated researchers, Available to DDRCC researchers | SCR_015607 | SciCrunch Registry | 2026-09-26 02:18:55 | 0 | ||||||||
|
Network for Pancreatic Organ Donors with Diabetes Resource Report Resource Website 100+ mentions Rating or validation data |
Network for Pancreatic Organ Donors with Diabetes (RRID:SCR_014641) | nPOD | biomaterial supply resource, material resource, tissue bank | A collaborative research project that supports nPOD approved diabetes investigators by freely providing rare and difficult-to-obtain tissues from type 1 and type 2 diabetes donors. Interested researchers are encouraged to apply to obtain nPOD tissues, or to request access to analyze cases in the nPOD Online Pathology site. Interested donors can contact nPOD directly for more information. | biosample, diabetes, type 1 diabetes, type 2 diabetes, donor, human, tissue, tissue supplier, pancreas, biomaterial supply resource, organization | is listed by: NIDDK Information Network (dkNET) | Type 1 diabetes, Diabetes | Public, Available to the research community, Must be an approved nPOD investigator to receive samples | SCR_014641 | SciCrunch Registry | Network for Pancreatic Organ Donors with Diabetes (nPOD), The Network for Pancreatic Organ Donors with Diabetes | 2026-09-26 02:18:53 | 194 | |||||||
|
Trans-Omics for Precision Medicine (TOPMed) Program Resource Report Resource Website 10+ mentions |
Trans-Omics for Precision Medicine (TOPMed) Program (RRID:SCR_015677) | TOPMED | biomaterial supply resource, data or information resource, database, material resource, tissue bank | Funding program for Precision Medicine genome sequencing from the National Institutes of Health, NHBLI. |
is listed by: NIDDK Information Network (dkNET) is related to: Broad Institute Genomics Platform is parent organization of: Phenotypes and eXposures Toolkit |
SCR_015677 | SciCrunch Registry | 2026-09-26 02:18:55 | 12 | |||||||||||
|
ABC Bacterial Transporter Systems Database Resource Report Resource Website |
ABC Bacterial Transporter Systems Database (RRID:SCR_016617) | ABC-BAC | data or information resource, database | Collection of classified bacterial ATP-binding cassette (ABC) transporter systems. The transporter systems identified fulfill the three roles characterized by the nucleotide-binding domain (NBD) , transmembrane domain (TMD), and solute-binding protein (SBP) domains. | collect, classified, bacterial, ATP, binding, cassette, transporter, system |
is listed by: NIAID is listed by: NIDDK Information Network (dkNET) |
Free, Available for download, Freely available | SCR_016617 | SciCrunch Registry | ABC Bacterial Transporter Systems, ABC-BAC | 2026-09-26 02:18:55 | 0 | ||||||||
|
Drug-Induced Liver Injury Network Resource Report Resource Website 1+ mentions |
Drug-Induced Liver Injury Network (RRID:SCR_001524) | DILIN | biomaterial supply resource, material resource | Prospective and retrospective registry of well-characterized cases of drug-induced liver disease. The goals of Network include the development of standardized procedures to identify and fully characterize bona fide cases of drug- and complementary and alternative medicines (CAM)-induced liver injury, and to conduct controlled, clinical studies that will include extensive collection of data, serum, DNA, and tissue specimens. Cases of liver injury due to herbal medications are also included. The network will also develop terminology and standardized definitions for DILI, and to develop causality assessment instruments that are sensitive, specific, and reproducible. DILIN is funded by a cooperative agreement and includes five clinical centers and a central data coordinating center. The research goals of DILIN are to: * Create a registry of carefully documented DILI cases * Identify clinical, immunological, and environmental risk factors for drug- and CAM-mediated hepatotoxicity * Create a bank of biological specimens consisting of DNA, plasma, and immortalized lymphocytes to facilitate detailed genetic analyses * Characterize the natural history of drug- and CAM-induced DILI for at least six months following enrollment * Develop the capability to recontact these individuals over an extended period of time so that additional studies exploring DILI mechanisms can be performed Two studies are being initiated by the network. In the Retrospective Study, the implicated drugs are restricted to isoniazid, phenytoin, combination clavulanic acid/amoxicillin, and valproic acid (Depakote), Nitrofurantoin, Trimethoprim-sulfamethoxazole, Minocycline, and Quinolone antibiotics. These drugs were chosen because they are frequently administered to patients not receiving other hepatotoxic drugs, making it easier to establish causality. Patients must be alive, and the date of onset of the DILI episode must be on or after January 1, 1994. In the Prospective Study, all incident cases of drug- and CAM-induced liver injury are being considered. Initial presentation to a healthcare professional must be within the previous six months. A detailed medication history of the implicated DILI drug together with all prescription, OTC, and herbal medications is being recorded. Liver and serological tests are being performed to characterize the injury and to exclude competing causes of liver injury. A blood sample is also being drawn for plasma storage and DNA isolation. These cases will be followed longitudinally to characterize the long-term effects of the DILI episode. For both studies, documented, clinically significant DILI must be recorded in the patient's medical charts so that a causal determination can be made. Patients will be excluded if they are unwilling or unable to provide a blood sample or participate in the genetics component. Children under two years of age at the time of enrollment are excluded due to blood-volume requirements. If you have patients who are eligible to participate in either study, please contact one the DILIN clinical sites. As a general policy, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites investigator-initiated research project applications for ancillary studies to ongoing, large-scale clinical trials, epidemiological studies, and disease databases supported by the Institute. These studies are focused on a wide range of diseases and conditions including diabetes, obesity, acute and chronic liver disease, chronic kidney disease, and benign prostatic hyperplasia, among others. | prescription drug, over-the-counter drug, alternative medicine, herbal product, supplement, serum, dna, tissue, blood, immortalized lymphocyte, drug, medication, quinolone antibiotic, isoniazid, phenytoin, clavulanic acid, amoxicillin, valproic acid, depakote, nitrofurantoin, trimethoprim-sulfamethoxazole, minocycline, diagnosis, hepatotoxicity, risk factor, genetic analysis |
is listed by: One Mind Biospecimen Bank Listing is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers has parent organization: Duke University; North Carolina; USA |
Liver injury, Hepatic injury, Drug-induced liver disease | NIDDK | Qualified investigators, Account required | nlx_152822 | https://dilin.dcri.duke.edu/ | SCR_001524 | SciCrunch Registry | 2026-09-26 02:19:03 | 6 | |||||
|
Diabetes Prevention Type 1 Resource Report Resource Website |
Diabetes Prevention Type 1 (RRID:SCR_001467) | DPT-1 | biomaterial supply resource, material resource | Data set and biosepecimens of a multi-center clinical trial to determine if treatment with beta-cell antigens can delay the onset of Type 1 Diabetes Mellitus (Type 1 DM) in non-diabetic relatives of persons with Type 1 DM. Insulin is a well characterized antigen specifically produced by beta-cells, and it was used for this purpose in the initial DPT-1 studies. The protocol for high risk subjects uses daily subcutaneous insulin injections and an annual course of intravenous insulin treatment, while the protocol for intermediate risk subjects uses daily doses of insulin administered orally. Neither injected nor oral insulin at the doses used were observed to delay or prevent diabetes, although further studies are needed to test whether oral insulin can delay diabetes in people in the intermediate risk group with high titers of insulin autoantibodies. | beta cell antigen, insulin, prevention, onset, subcutaneous injection, oral, intravenous, treatment, randomized, controlled trial, drug therapy, delay |
is listed by: One Mind Biospecimen Bank Listing is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: Diabetes Research Centers |
Type 1 diabetes, Diabetes | NIDDK UC4 DK097835 | Free, Freely Available | nlx_152696 | https://www.niddkrepository.org/niddk/jsp/public/dataset.jsp#DPT-1 | SCR_001467 | SciCrunch Registry | Diabetes Prevention Trial--Type 1 (DPT-1) dataset, DPT-1 (The Diabetes Prevention Type 1) | 2026-09-26 02:19:02 | 0 | ||||
|
NIH Chronic Prostatitis Symptom Index Resource Report Resource Website |
NIH Chronic Prostatitis Symptom Index (RRID:SCR_001482) | CPSI, NIH-CPSI | assessment test provider, material resource | Questionnaire developed by physicians in NIDDK's Chronic Prostatitis Collaborative Research Network that can help physicians to accurately measure the severity of prostatitis symptoms and their impact on a patient's lifestyle. The CPSI questionnaire assesses pain, urination, and the effect of chronic prostatitis on daily activities. With this information, researchers and physicians can reliably evaluate whether potential treatments are working. The questionnaire was originally published in the Journal of Urology in August 1999 (Vol. 162, pages 369-375). It is available as a PDF document in English, Spanish, German and Korean. | pain, symptom, quality of life, male | is listed by: NIDDK Information Network (dkNET) | Prostatitis | NIDDK | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_152732 | SCR_001482 | SciCrunch Registry | Chronic Prostatitis Symptom Index, National Institutes of Health Chronic Prostatitis Symptoms Index | 2026-09-26 02:19:03 | 0 | |||||
|
Biospecimens/Biorepositories: Rare Disease-HUB (RD-HUB) Resource Report Resource Website |
Biospecimens/Biorepositories: Rare Disease-HUB (RD-HUB) (RRID:SCR_004327) | RD-HUB | biomaterial supply resource, material resource | A database of biospecimens collected, stored, and distributed by biorepositories in the United States and around the globe. Its goals are: To help and assist interested parties and investigators search, locate, and identify desired biospecimens needed for their research; to facilitate collaboration and sharing of material and data among investigators across the globe; to accelerate research to facilitate the discovery of new treatments, therapeutics and eventually cures for rare diseases as well as common diseases; to identify, locate and increase the awareness of existing biorepositories across the globe; and to link the RD-HUB with the Global Rare Diseases Patient Registry and Data Repository (GRDR). | rare disease, disease, public |
lists: NIDDK Central Repository lists: National Disease Research Interchange is listed by: NIH Data Sharing Repositories is listed by: One Mind Biospecimen Bank Listing is listed by: Accelerated Cure Project MS Repository is listed by: Cooperative Human Tissue Network Western Division at Vanderbilt University Medical Center is listed by: NIDDK Information Network (dkNET) is related to: GRDR has parent organization: Office of Rare Diseases Research |
Rare disease, Aging | NIH | PMID:20609392 | Public, The community can contribute to this resource | nlx_143682 | http://biospecimens.ordr.info.nih.gov/ | SCR_004327 | SciCrunch Registry | Biospecimens / Biorepositories: Rare Disease-HUB, Biospecimens/Biorepositories: Rare Disease-HUB, Rare Disease-HUB | 2026-09-26 02:19:07 | 0 | |||
|
Cooperative Study Group for Autoimmune Disease Prevention Resource Report Resource Website |
Cooperative Study Group for Autoimmune Disease Prevention (RRID:SCR_006803) | CSGADP | knowledge environment, resource | Collaborative network of investigators with a focus on prevention of autoimmune disease, defined as halting the development of autoimmune disease prior to clinical onset by means other than global immunosuppression, and an emphasis on Type 1 diabetes. Its mission is to engage in scientific discovery that significantly advances knowledge for the prevention and regulation of autoimmune disease. The specific goals enunciated in pursuit of this mission are: * To create improved models of disease pathogenesis and therapy to better understand immune mechanisms that will provide opportunities for prevention strategies * To use these models as validation platforms with which to test new tools applicable to human studies * To encourage core expertise and collaborative projects designed for rapid translation from animal to human studies, emphasizing the development of surrogate markers for disease progression and/or regulation which can be utilized in the context of clinical trials | prevention, clinical, immune, model, disease pathogenesis, therapy |
is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources |
Type 1 diabetes, Diabetes, Autoimmune disease | NIAID ; NIDDK ; NICHD ; NIH Office of Research on Womens Health ; Juvenile Diabetes Research Foundation International |
nlx_152797 | SCR_006803 | SciCrunch Registry | 2026-09-26 02:19:10 | 0 | |||||||
|
Type 1 Diabetes - Rapid Access to Intervention Development Resource Report Resource Website |
Type 1 Diabetes - Rapid Access to Intervention Development (RRID:SCR_000203) | T1D-RAID | resource, service resource | NOTE: The T1D-RAID program is not currently accepting applications. Cooperative program that makes available, on a competitive basis, NCI resources for the pre-clinical development of drugs, natural products, and biologics to facilitate translation to the clinic of novel, scientifically meritorious therapeutic interventions for type 1 diabetes and its complications. A partial listing of those services includes: high-throughput screening, studies in animal models, formulation, pharmacology and toxicology studies, and bulk substances acquisition. Requests to T1D-RAID are brief (20 pages or less), and should clearly outline the resources required to ready the proposed therapeutic agent for clinical trials. T1D-RAID should enable entry into the clinic of promising molecules that are not otherwise likely to receive an adequate and timely clinical test. T1D-RAID is designed to accomplish the tasks that are rate-limiting in bringing discoveries from the laboratory to the clinic. Once a project has been approved, NIDDKstaff interact directly with the Principal Investigator (PI). NCI contractors perform the T1D-RAID-approved tasks under the direction of NIDDKand NCI staff. The required tasks will vary from project to project. In some cases T1D-RAID will support only one or two key missing steps necessary to bring a compound to the clinic; in other cases it may be necessary to supply the entire portfolio of development requirements needed to file an IND. Examples of tasks that can be supported by T1D-RAID include, but are not limited to: * Definition or optimization of dose and schedule for in vivo activity * Development of pharmacology assays * Conduct of pharmacology studies with a pre-determined assay * Acquisition of bulk substance (GMP and non-GMP) * Scale-up production from lab-scale to clinical-trials lot scale * Development of suitable formulations * Development of analytical methods for bulk substances * Production of dosage forms * Stability assurance of dosage forms * Range-finding initial toxicology * IND-directed toxicology, with correlative pharmacology and histopathology * Planning of clinical trials * Regulatory affairs, so that FDA requirements are likely to be satisfied by participating investigators seeking to test new molecular entities in the clinic * IND filing advice The output of T1D-RAID activities will be both products and information that will be made fully available to the originating investigator for support of an IND application and clinical trials. T1D-RAID does not sponsor clinical trials. | therapeutic, drug, drug development, pharmacogenomics |
is listed by: NIDDK Information Network (dkNET) is related to: Type 1 Diabetes Preclinical Testing Program has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Type 1 diabetes, Diabetes | NCI ; NIDDK |
nlx_152742 | SCR_000203 | SciCrunch Registry | Type 1 Diabetes - Rapid Access to Intervention Development (T1D-RAID) | 2026-09-26 02:19:42 | 0 | ||||||
|
Diabetes Prevention Program Outcomes Study Resource Report Resource Website |
Diabetes Prevention Program Outcomes Study (RRID:SCR_001502) | DPPOS | clinical trial, data or information resource, database, resource | Observational clinical trial studying the long term effect of diet and exercise and the diabetes medication, metformin, on the delay of type 2 diabetes in participants of the Diabetes Prevention Program (DPP). The Diabetes Prevention Program (DPP) was a multi-center trial examining the ability of an intensive lifestyle or metformin to prevent or delay the development of diabetes in a high risk population due to the presence of impaired glucose tolerance (IGT). The DPP has ended early demonstrating that lifestyle reduced diabetes onset by 58% and metformin reduced diabetes onset by 31%. The DPPOS is designed to take advantage of the scientifically and clinically valuable DPP participants. This group of participants is nearly 50% minority and represents the largest IGT population ever studied. Clinically important research questions remain that focus on 1)durability of the prior DPP intervention, 2) determination of the clinical course of precisely known new onset diabetes, in particular regarding CVD, CVD risk factors and atherosclerosis and microvascular disease, 3)close examination of these topics in men vs women and in minority populations. More than 87% of the original surviving DPP cohort has joined DPPOS as of December, 2007 and, to date, after 5 years of DPPOS and 10 years of combined DPP/DPPOS, 93% of the DPPOS cohort continue to attend annual follow-up visits. Interim analyses performed after 5 years of DPPOS have demonstrated a durable effect of diabetes prevention associated with the lifestyle and metformin interventions with 34 and 19% reductions in diabetes incidence, respectively, compared with the placebo group. Interim analyses also reveal significant reductions from baseline in CVD risk factors in the lifestyle intervention group, but with decreased utilization of glucose-lowering and lipid-lowering medications. Analyses of the participants in the placebo group who have developed diabetes during DPP/DPPOS, compared with those who have remained non-diabetic, reveal an increased frequency of retinopathy and microalbuminuria. The current, updated protocol describes the DPPOS including the revisions incorporated to complete the second five-years of the study. DPPOS participants have blood samples stored at the time of each annual visit. Specimens are stored at the study CBL until after the primary study outcomes are reported. DNA samples were previously collected and are stored at the NIDDKsample repository for DPP participants. | adult human, late adult human, male, female, caucasian, african-american, hispanic american, asian, pacific islander-american, american indian, metformin, microangiopathic, neuropathic, outcome, placebo, diabetic retinopathy, diabetic neuropathy, albuminuria, renal failure, macrovascular disease, cardiovascular disease, atherosclerosis, risk factor, amputation, hospitalization, physical activity, nutrition, body mass, obesity, dietary behavior, exercise behavior, physical functioning, quality of life, health care cost, cognitive performance, urinary incontinence, observational, microvascular disease, blood, dna |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Central Repository has parent organization: George Washington University; Washington D.C.; USA |
Type 2 diabetes, Diabetes | NIDDK U01DK048514; NIDDK U01DK048437; NIDDK U01DK048413; NIDDK U01DK048406; NIDDK U01DK048380; NIDDK U01DK048397 |
Free, Freely available | nlx_152800 | SCR_001502 | SciCrunch Registry | 2026-09-26 02:19:44 | 0 | ||||||
|
Vanderbilt Diabetes Research and Training Center Islet Procurement and Analysis Core Resource Report Resource Website |
Vanderbilt Diabetes Research and Training Center Islet Procurement and Analysis Core (RRID:SCR_000896) | VU IPA Core | access service resource, core facility, resource, service resource | THIS RESOURCE IS NO LONGER IN SERVICE. Documented on August 13,2025.Core facility that provides access to isolated pancreatic islets from normal and diabetic models and performs islet functional analysis. The IPA Core also provides solutions for high-resolution whole slide imaging and access to image analysis tools for quantitative assessment of pancreatic islet morphology. | diabetes, pancreas, islet functional analysis, pancreatic islet morphology |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: Vanderbilt University; Tennessee; USA has parent organization: Vanderbilt Diabetes Research and Training Center is organization facet of: Vanderbilt Diabetes Research and Training Center |
Diabetes | NIDDK DK020593 | THIS RESOURCE IS NO LONGER IN SERVICE | nlx_156666 | http://eagle-i.ea.vanderbilt.edu/i/00000139-b6a3-c300-b341-4bb480000000 | SCR_000896 | SciCrunch Registry | 2026-09-26 02:19:43 | 0 | |||||
|
Penn Diabetes Research Center Mouse Phenotyping Physiology and Metabolism Core Resource Report Resource Website |
Penn Diabetes Research Center Mouse Phenotyping Physiology and Metabolism Core (RRID:SCR_000888) | access service resource, core facility, resource, service resource | Core which provides researchers with resources for performing metabolic studies in mice. It also provides services, innovative techniques, and helpful consultation to both experienced and novice investigators with regards to metabolic questions. | mouse phenotyping, metabolism research |
is listed by: Eagle I is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pennsylvania; Philadelphia; USA has parent organization: Penn Diabetes Research Center is organization facet of: Penn Diabetes Research Center |
Diabetes | NIDDK P30DK19525 | Available to the DRC community, Acknowledgement requested | nlx_156493 | SCR_000888 | SciCrunch Registry | 2026-09-26 02:19:43 | 0 | |||||||
|
Frequent Hemodialysis Network Daily Trial Resource Report Resource Website 1+ mentions |
Frequent Hemodialysis Network Daily Trial (RRID:SCR_001527) | FHN Daily Trial | clinical trial, resource | Randomized controlled clinical trial to understand how increasing hemodialysis to six times a week from the standard of three times a week may result in improved heart health. Subjects were recruited from dialysis units associated with designated Clinical Centers in the U.S. and Canada and followed for 1 year. Subjects will be randomized to either conventional hemodialyis Daily HD delivered for at least 2.5 hours (typically 3 to 4 hours), 3 days per week, or to more frequent hemodialysis delivered for 1.5 - 2.75 hours, 6 days per week. The study has two co-primary outcomes: 1) a composite of mortality with the change over 12 months in left ventricular mass by magnetic resonance imaging, and 2) a composite of mortality with the change over 12 months in the SF-36 RAND physical health composite (PHC) quality of life scale. In addition, main secondary outcomes have been designated for each of seven outcome domains: 1) cardiovascular structure and function (change in LV mass), 2) health-related quality of life/physical function (change in the PHC), 3) depression/burden of illness (change in Beck Depression Inventory), 4) nutrition (change in serum albumin), 5) cognitive function (change in the Trail Making Test B), 6) mineral metabolism (change in average predialysis serum phosphorus), and 7) clinical events (rate of non-access hospitalization or death). Hypertension and anemia are also main outcome domains, but without designation of single first priority outcomes. | hemodialysis, cardiovascular, kidney, heart |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is related to: Frequent Hemodialysis Network Nocturnal Trial has parent organization: NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases |
Hemodialysis, End Stage Renal Disease | NIDDK | PMID:21091062 PMID:17164834 PMID:17699439 |
Free, Freely available | nlx_152828 | https://www.niddk.nih.gov/news/for-reporters/frequent-hemodialysis-network-daily-trial/Pages/default.aspx | SCR_001527 | SciCrunch Registry | Frequent Hemodialysis Network (FHN) Daily Trial | 2026-09-26 02:19:44 | 1 | |||
|
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C Resource Report Resource Website |
Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (RRID:SCR_001553) | Virahep-C | clinical trial, resource | Study designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not previously treated with either interferon or ribavirin. Reasons for differences in response, regardless of race, will be studied. All patients were treated with combination therapy of pegylated interferon and ribavirin for 48 weeks, and were followed for an additional 48 week safter cessation of therapy. 400 patients, half African-American and half Caucasian American, from 8 clinical centers with the goals of establishing rates of response to optimal current therapy in the two ethnic groups, identify factors predictive of response, establish patterns of viral kinetics in response to antiviral therapy, and test hypotheses concerning viral and host factors determining response to therapy. Four ancillary studies designed to elucidate biological and virological basis for non-response are also included in Virahep-C. Additionally, the study has central facilitates for pathology, the virological testing laboratory and a serum/tissue repository. | african-american, pegylated interferon, drug, ribavirin, caucasian-american, chronic hepatitis c genotype 1, biomaterial supply resource, efficacy, treatment, adult human, male, female, interferon, resistance, antiviral therapy, serum, tissue |
is listed by: One Mind Biospecimen Bank Listing is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) is listed by: NIDDK Research Resources has parent organization: University of Pittsburgh; Pennsylvania; USA |
Chronic hepatitis C, Hepatitis C virus | NIDDK U01DK60329 | Free, Freely available | nlx_152861 | http://www.edc.gsph.pitt.edu/virahepc/, http://www.virahepc.org/ | SCR_001553 | SciCrunch Registry | Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C), Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C | 2026-09-26 02:19:44 | 0 | ||||
|
TINSAL-T2D Resource Report Resource Website 1+ mentions |
TINSAL-T2D (RRID:SCR_001546) | TINSAL-T2D, TINSAL-T2D-II | clinical trial, resource | Nationwide, randomized, double blind, multi-center research study to determine whether the drug salsalate, a member of the commonly used Non-Steroidal Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2 diabetes. The study is conducted in two stages. The primary objective of the first stage is to select a dose of salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic control. The primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and cardiac risk. | salsalate, drug, intervention, treatment, hba1c, inflammation, obesity, metabolic syndrome, adult human, male, female, non-steroidal anti-inflammatory drug, diabetes management, placebo, glycemic control |
is listed by: ClinicalTrials.gov is listed by: NIDDK Information Network (dkNET) has parent organization: Joslin Diabetes Center |
Type 2 diabetes, Inflammation, Metabolic syndrome, Cardiac disease, Obesity | NIDDK 5R01DK095327 | PMID:20231565 PMID:17959861 |
Free, Freely available | nlx_152855 | https://clinicaltrials.gov/ct2/show/NCT00392678 | http://www.tinsal-t2d.org/ | SCR_001546 | SciCrunch Registry | Targeting Inflammation Using Salsalate for Type 2 Diabetes-stage II, Targeting INflammation using SALsalate for Type 2 Diabetes | 2026-09-26 02:19:44 | 1 | ||
|
Study of Nutrition in Acute Pancreatitis Resource Report Resource Website |
Study of Nutrition in Acute Pancreatitis (RRID:SCR_001544) | SNAP | clinical trial, resource | Randomized multi-center clinical trial designed to test whether duodenojejunal (DJ) feeding is more effective than nasogastric (NG) feeding in providing enteral nutrition to patients with severe acute pancreatitis. SNAP will enroll participants with severe acute pancreatitis admitted to the intensive care unit at eight clinical centers. Upon enrollment, participants are assigned to NG or DJ feeding and managed for up to 28 days or until weaned on to solid food. Follow-up continues until participants are discharged from the hospital or for a maximum of 60 days. Outcomes relate to feeding tolerance and failure, nutritional status, risk for life-threatening pancreatic/systemic complications, and hospital mortality. | duodenojejunal feeding, naso gastric feeding, enteral nutrition, feeding tolerance, outcome, acute pancreatitis, distal jejunal feeding, intervention, nutrition, treatment, adult human, male, female, pancreas |
is listed by: ClinicalTrials.gov is listed by: NIDDK Research Resources is listed by: NIDDK Information Network (dkNET) has parent organization: University of Pittsburgh; Pennsylvania; USA |
Pancreatitis | NIDDK | Free, Freely available | nlx_152854 | SCR_001544 | SciCrunch Registry | 2026-09-26 02:19:44 | 0 |
Can't find your Tool?
We recommend that you click next to the search bar to check some helpful tips on searches and refine your search firstly. Alternatively, please register your tool with the SciCrunch Registry by adding a little information to a web form, logging in will enable users to create a provisional RRID, but it not required to submit.
Welcome to the dkNET Resources search. From here you can search through a compilation of resources used by dkNET and see how data is organized within our community.
You are currently on the Community Resources tab looking through categories and sources that dkNET has compiled. You can navigate through those categories from here or change to a different tab to execute your search through. Each tab gives a different perspective on data.
If you have an account on dkNET then you can log in from here to get additional features in dkNET such as Collections, Saved Searches, and managing Resources.
Here is the search term that is being executed, you can type in anything you want to search for. Some tips to help searching:
If you are logged into dkNET you can add data records to your collections to create custom spreadsheets across multiple sources of data.
Here are the facets that you can filter the data by.
If you have any further questions please check out our FAQs Page to ask questions and see our tutorials. Click this button to view this tutorial again.
The NIDDK Information Network (dkNET) serves the needs of basic and clinical investigators by providing seamless access to large pools of data and research resources relevant to the mission of The National Institute of Diabetes Digestive and Kidney Diseases (NIDDK). dkNET is hosted at University of California San Diego, and is supported by NIH NIDDK grant U24DK097771.
Email: info_at_ dknet.org
